Drug intelligence / Profile preview

DermaTopic

Development stage: Preclinical
Lead developer: Almapharm
Modality: Small Molecules, Hydrogel Systems → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

DermaTopic is a commercial medicated shampoo developed by Almapharm for dogs with mild to moderate allergic pruritus without secondary skin infections. It is a combination product containing chlorhexidine, lactoferrin, piroctone olamine, chitosan, and essential fatty acids, designed to alleviate itching and improve skin health through its antiseptic, antimicrobial, antifungal, film-forming, and anti-inflammatory properties.

Brand names: DermaTopic

Beyond the preview

Go deeper on DermaTopic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DermaTopic.

Explore the full profile